Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation
NCT ID: NCT01008683
Last Updated: 2009-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2009-11-30
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In these patients the investigators will measure the specific antibody production.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients
NCT01254955
Influenza Vaccine Responses as a Means of Assessing Immune Competence in Chimeric Kidney/Stem Cell Transplant Recipients
NCT02623075
Immune Response to Influenza Vaccine in Islet Cell Transplant Recipients
NCT01149382
Seasonal Flu Vaccine in Adult Transplant Recipients
NCT01258023
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
NCT01808456
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In these patients we will measure the specific antibody production. Blood sample 5 ml will be drawn before the first vaccine, before the second, and 3-4 weeks after the 2nd dose.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stem cell and and heart transplant patients
Stem cell and and heart transplant patients
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hadassah Medical Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
HMO
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Dan Engelhard
Role: PRINCIPAL_INVESTIGATOR
Hadassah
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah Medical Organization
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
engelhard-HMO-CTIL
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.